An intraperitoneal dose of 5 mg kg−1 of ivermectin administered to our tumor‐bearing mice was well‐tolerated, which aligns well with the previously reported LD50 of 30 mg kg−1 for intraperitoneal ivermectin administration in healthy mice.[19] Consistent with our data for Gsdmc silencing (Figure 4G,H), treatment of the orthotopic PDAC model with ivermectin (Figure 5K) also enhanced the influx of CD4+ and CD8+ T cells, and NK cells (Figure 5L), and subsequently inhibited tumor progression with virtual ablation of the metastases in liver and lung (Figure 5M). Here, CD8A is linked to neoplasm.